Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients

NCT03079011 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03079011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03079011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2017
Completion date
September 22, 2025
Enrollment
1,017 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer